more readable form here :)
Hepatitis B therapy pipeline
Project / Company / Pharmacology / Trial ID / Data due?
GS-9620 Giled Sciences TLR7 agonist NCT02166047 & NCT02579382 Imminent & Dec 2016
GS-4774 Sciences/Globeimmune Therapeutic vaccine NCT02174276 Imminent
Myrcludex B Viral entry inhibitor NCT02637999 Imminent
REP 2139 Replicor HBsAg release inhibitor
NCT02726789 Sep 2016
ARC-520 Arrowhead Pharmaceuticals RNAi therapeutic NCT02604199 and 4 others Oct 2016
ARB-1467 Arbutus Biopharma RNAi therapeutic NCT02631096 Oct 2016
CMX157 Chimerix/Contravir NNRTI NCT02710604 Oct 2016
GC1102 Green Cross (Korea) Recombinant hep B immunoglobulin NCT02569372 May 2017
RO6864018 Roche Not disclosed NCT02391805 Sep 2017
SB 9200 Spring Bank Pharmaceuticals RIG-I & NOD2 activator NCT02751996 Dec 2017
REP 2165 Replicor HBsAg release inhibitor NCT02565719 Sep 2018
NVR 3-778 Johnson & Johnson Capsid inhibitor NCT02401737 Imminent
JNJ-56136379 Johnson & Johnson Not disclosed NCT02662712 Nov 2016
IONIS-HBV-LRx GlaxoSmithKline/Ionis Hepatitis B antisense NCT02647281 Nov 2016
HepTcell (FP-02.2) Altimmune Therapeutic vaccine NCT02496897 Feb 2017 RO7020322 Roche Not disclosed NCT02604355 Apr 2017
ARC-521 Arrowhead Pharmaceuticals ccc DNA-targeting RNAi NCT02797522 Jun 2017
TG1050 Transgene Therapeutic vaccine NCT02428400 Mar 2018
INO-1800/RG7944 Inovio Pharmaceuticals Therapeutic vaccine NCT02431312 Dec 2018
RG7834 Roche Not disclosed – (1st pt in Q4 2015)
AIC649 Aicuris Therapeutic vaccine – –
EYP001 Enyo Pharma Farnesoid X receptor agonist – –
GSK3228836 GlaxoSmithKline/Ionis Hepatitis B antisense – –
Source: EvaluatePharma and Clinicaltrials.gov.
This is a very comprehensive and timely article about HBV drugs in development. ABX203 was not mentioned, even though one clinical trial is still on-going. Most of the others are well-known to us all - very hard to get excited about.
It would be interesting to know more about the "undisclosed mechanism" of the Johnson& Johnson and Roach's drugs. It is hard to tell whether they do not want to disclose because they are just like the others or represent some new approaches.
I feel the only leading HBV drug on pipeline is ARWR( Arc-520).
It is 5.5 log reduction in hbvdna, not HBsAg. Since patients are on Entecavir, these types of reduction in hbvdna are not unusual.
Press release from Abivax:
* Post-treatment monitoring of patients will be continued as per protocol in order to provide additional insight on clinical trial outcomes and secondary endpoints
* Future development of ABX203 under review, including addition of an adjuvant, new administration schedules and therapeutic combinations
i feel like some new drug by 2020, lets c.